A Randomized, Double-blind Controlled Clinical Study to Evaluate the Efficacy and Safety of Minoxidil Topical 2% Nanosuspension with Aqueous Base in the Treatment of Androgenetic Alopecia Areata

Shahla Mirzaeei; Ashkan Barfar; Saba Mehrandish; Ali Ebrahimi

doi:10.4103/jrptps.JRPTPS_25_21

Outlines

Abstract
Copyright

https://doi.org/10.4103/jrptps.JRPTPS_25_21

A Randomized, Double-blind Controlled Clinical Study to Evaluate the Efficacy and Safety of Minoxidil Topical 2% Nanosuspension with Aqueous Base in the Treatment of Androgenetic Alopecia Areata

Author(s):

Shahla Mirzaeei

^{1, 1,*},

Ashkan Barfar²,

Saba Mehrandish

²,

Ali Ebrahimi³

1Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

2Student Research Committee, School of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran

3Dermatology Department, Kermanshah University of Medical Sciences, Kermanshah, Iran

Journal of Reports in Pharmaceutical Sciences:Vol. 10, issue 2; 279-86

Published online:Dec 17, 2021

Article type:Research Article

Received:Feb 20, 2021

Accepted:May 29, 2021

How to Cite:Shahla MirzaeeiAshkan BarfarSaba MehrandishAli EbrahimiA Randomized, Double-blind Controlled Clinical Study to Evaluate the Efficacy and Safety of Minoxidil Topical 2% Nanosuspension with Aqueous Base in the Treatment of Androgenetic Alopecia Areata.J Rep Pharm Sci.10(2):e146965.https://doi.org/10.4103/jrptps.JRPTPS_25_21.

Abstract

Background and Purpose: Using the commercially manufactured forms of minoxidil, the only approved topical drug preparation for hair regrowth in patients with androgenetic alopecia (AGA) comes across with challenges such as limited permeation through the superficial layers of the skin to reach the site of action and topical adverse reactions like itching and inflammation occur because of the ethanol in the formulations. In this study, a novel nanosuspension formulation with an aqueous base was prepared and evaluated to overcome the discussed challenges.
Materials and Methods: The nanosuspension formulation was characterized by size, zeta potential, morphology, and in vitro release. Seventy patients were subjected to use either 1 mL of nanosuspension or the commercial product twice daily for six months and were then examined for changes in hair follicle diameter and hair density within a 1 × 1-cm2 area of the scalp as the primary endpoints besides any adverse reaction manifestation as the secondary endpoint.
Results: The nanosuspension formulation showed uniform morphology, 200-nm particle size, and suitable zeta potential that ensures the stability. The in vitro release study exhibited almost 90% release in the first 6 h. It was observed that there were no significant differences between the efficacy of aqueous-based topical 2% nanosuspension of minoxidil and the commercial product in the treatment of AGA (P > 0.05). However, the aqueous-based topical 2% nanosuspension formulation showed better safety and tolerability compared to the marketed profile.
Conclusions: It could be concluded that aqueous-based topical 2% nanosuspension is a suitable form with enhanced patient compliance compared to commercially manufactured products.

Keywords

Androgenetic alopecia areata

clinical study

minoxidil

nanosuspension

comments

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Metrics

Get Permission (article level)

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

Shahla Mirzaeei:[PubMed][Scholar]
Ashkan Barfar:[PubMed][Scholar]
Saba Mehrandish:[PubMed][Scholar]
Ali Ebrahimi:[PubMed][Scholar]